G0S2 Antibody

Manufactured by Genomic Antibody Technology™. GAT FAQs

G0S2 (G0/G1 switch protein 2) was discovered in lectin activated lymphocytes during G0 to G1 transition favoring cell division and postulated to regulate G0/G1 phase either by releasing lymphocytes from quiescence (G0 to G1 transition) or via promoting proliferation (G1 to S phase transition). Subsequently, this multifaceted protein was documented to implicate in proliferation, metabolism, inflammation, and carcinogenesis. In mouse, G0S2 was shown to express in adipose tissue and its direct up-regulation by PPAR-gamma was associated with cell-cycle withdrawal, growth arrest and adipogenic differentiation of preadipocytes. G0S2 has been proposed to inhibit hematopoietic stem cell proliferation and to promote stem cell quiescence (G0 phase). G0S2 features a CpG-rich island that potentially allows for germ-line expression and its promoter region contains binding sites for transcription factors AP1, AP2, AP3, NFAT and sequence motifs which responds to transcriptional activation stimulated by lectin, retinoic acid, PPARs agonists, glucose and insulin. G0S2 is epigenetically silenced in head/neck and squamous lung cancer, and cisplatin-resistant cancer cells advocating for its role in tumorigenesis and chemoresistance. G0S2 expression is elevated in endometriosis, bronchial epithelial cells treated with retinoic acid, senescent dermal fibroblasts, BM cells from patients with rheumatoid arthritis, and peripheral mononuclear cells from patients with vasculitis and psoriasis.

This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.

Array NBP1-71690

• G0S2 Antibodies
• G0S2 Lysate
• G0S2 Protein